Literature DB >> 28300447

Sweet Syndrome: Clinical Features, Histopathology, and Associations of 83 Cases.

Jose Ricardo Casarin Costa1, Anangelica Rodrigues Virgens1, Luisa de Oliveira Mestre1, Natasha Favoretto Dias1, Luciana Paula Samorano1, Neusa Yuriko Sakai Valente1, Cyro Festa Neto1.   

Abstract

BACKGROUND: Sweet syndrome (SS) is an infrequent skin disease characterised by sudden onset of fever, leukocytosis, neutrophilia, and tender erythematous plaques infiltrated by neutrophils. Multiple conditions have been associated with this syndrome.
OBJECTIVES: The aim of this study was to evaluate the clinical, epidemiological, laboratory, and histopathological findings and associations of patients with SS.
METHODS: We conducted a retrospective study of 83 patients with SS followed between January 1, 2006, and January 31, 2015.
RESULTS: Of the patients, 82% were female; the mean age at onset was 48 years. Clinical presentation was mainly characterised by erythematous and edematous plaques, mostly on upper extremities and trunk. Fever was observed in 32%; 60% presented leukocytosis and 39% neutrophilia. On histopathological examination, neutrophilic and lymphohistiocytic infiltrate and edema were the most frequent findings. Fourteen percent of patients had malignancy or hematologic disorders, 26% were classified as having drug-induced SS, and 24% noted recent infection. Only 2 cases occurred during pregnancy. Systemic corticosteroid was the most common choice of treatment, with excellent response. In malignancy-associated SS, the mean hemoglobin level was lower ( P = .01) and the erythrocyte sedimentation rate (ESR) was higher ( P = .04) in comparison to classic and drug-induced SS. Leukocytoclasia was associated with higher risk of recurrence ( P = .01).
CONCLUSION: All patients with SS deserve careful investigation of possible underlying conditions. Higher ESR and lower hemoglobin levels might reinforce the need of malignancy screening. Also, leukocytoclasia appears to be a potential marker of higher recurrence rate, demanding closer and longer follow-up.

Entities:  

Keywords:  Sweet syndrome; drug-induced; erythematous plaques; fever; leukocytosis; neutrophilic dermatosis; paraneoplastic phenomenon

Mesh:

Substances:

Year:  2017        PMID: 28300447     DOI: 10.1177/1203475417690719

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  3 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

Review 2.  [Rheumatoid symptoms in patients with hematologic neoplasms].

Authors:  S Kleinert; P La Rosée; K Krüger
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

3.  Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease.

Authors:  Joseph Sleiman; Asif A Hitawala; Benjamin Cohen; Katie Falloon; Marian Simonson; Benjamin Click; Urmi Khanna; Anthony P Fernandez; Florian Rieder
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 9.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.